Intracranial activity of alectinib
(pooled analysis of phase II studies)
Data cut-off for both studies 27 April 2015
Gadgeel, et al. J Clin Oncol 2016
Best intracranial response
70
50
-100
-90
-80
-70
-60
-50
-40
-30
-20
-10
0
10
20
30
Sum of longest diameter,
max. decrease from baseline (%)
60
40
CNS ORR 64% (baseline measurable CNS disease)
Patients
Yes (n=34)
No (n=16)
Prior CNS radiation
INDICACIÓN NO APROBADA, EN INVESTIGACIÓN
